Haynes Nancy-Ellen, Scott Nathan R, Chen Li C, Janson Cheryl A, Li Jia Kui, Lukacs Christine M, Railkar Aruna, Tozzo Effie, Whittard Toni, Brown Nicholas F, Cheung Adrian Wai-Hing
Hoffmann-La Roche Inc. , pRED, Pharma Research & Early Development, DTA Metabolism, 340 Kingsland Street, Nutley, New Jersey 07110, United States.
ACS Med Chem Lett. 2012 Aug 8;3(9):764-8. doi: 10.1021/ml300175c. eCollection 2012 Sep 13.
3-[4-((1S,2S,3R,5S,7S)-5-Hydroxyadamantan-2-ylcarbamoyl)benzyl]-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester (4) was identified as a novel, druglike and selective quinolone pan JNK inhibitor. In this communication, some of the structure-activity relationship of the azaquinolone analogues leading to 4 is discussed. The focus is on how changes at the amide functionality affected the biochemical potency, cellular potency, metabolic properties, and solubility of this class of JNK inhibitors. Optimization of these properties led to the identification of the adamantyl analogue, 4. 4 achieved proof of mechanism in both rat and mouse TNF-α challenge models.
3-[4-((1S,2S,3R,5S,7S)-5-羟基金刚烷-2-基氨基甲酰基)苄基]-4-氧代-1-苯基-1,4-二氢-[1,8]萘啶-2-羧酸甲酯(4)被鉴定为一种新型、类药物且具有选择性的喹诺酮类泛JNK抑制剂。在本通讯中,讨论了导致化合物4的氮杂喹诺酮类似物的一些构效关系。重点在于酰胺官能团的变化如何影响这类JNK抑制剂的生化活性、细胞活性、代谢性质和溶解度。对这些性质的优化导致了金刚烷基类似物4的鉴定。化合物4在大鼠和小鼠TNF-α激发模型中均实现了作用机制验证。